AbbVie (NYSE:ABBV) Shares Up 2.6% – What’s Next?

AbbVie Inc. (NYSE:ABBV)’s share price was up 2.6% during trading on Tuesday . The stock traded as high as $266.92 and last traded at $263.49. Approximately 6,790,808 shares were traded during trading, a decline of 4% from the average session volume of 7,037,222 shares. The stock had previously closed at $256.91.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RINVOQ gained two important European approvals. The European Commission authorized RINVOQ for severe alopecia areata in adults and adolescents aged 12 and older, supported by Phase 3 data showing significant scalp, eyebrow and eyelash regrowth. It was also approved for non-segmental vitiligo, making it the first and only systemic treatment approved for that condition in the European Union. The expanded indications could increase RINVOQ’s long-term revenue potential and help diversify AbbVie’s growth beyond its established products. RINVOQ alopecia areata approval RINVOQ vitiligo approval
• Positive Sentiment: AbbVie started a first-in-human Phase 1 trial of ABBV-859. The early-stage drug candidate adds to the company’s development pipeline, but the trial is an initial safety and dosing study, so any commercial benefit is years away and remains uncertain. ABBV-859 Phase 1 trial
• Positive Sentiment: Investor positioning and estimates remain supportive. Call-option activity was above typical levels, while Erste Group modestly raised its 2027 EPS forecast to $16.40. AbbVie’s 53-year dividend-growth record also continues to appeal to income-oriented investors. AbbVie call options activity
• Neutral Sentiment: Allergan Aesthetics announced the return of JUVÉDERM Day on August 19, offering promotions to Allē members. The event supports brand engagement but is unlikely to materially affect near-term AbbVie results. JUVÉDERM Day announcement
• Neutral Sentiment: Investors are preparing for AbbVie’s second-quarter results on July 31. The upcoming report could reset expectations for Skyrizi, RINVOQ and the company’s outlook. Goldman Sachs AbbVie earnings outlook
• Negative Sentiment: AbbVie’s proposed acquisition of Apogee Therapeutics faces a law-firm investigation into the deal price and sales process. Although the investigation targets Apogee’s transaction, any delay or increased scrutiny could create uncertainty around AbbVie’s planned $135.11-per-share cash acquisition and integration strategy. Apogee transaction investigation
• Negative Sentiment: Valuation is a key counterweight: commentary notes that ABBV’s substantial multiyear advance has left market-based multiples looking expensive, even though some intrinsic-value models indicate additional upside. Erste Group also trimmed its 2026 EPS estimate slightly to $14.05.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Royal Bank Of Canada boosted their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. JPMorgan Chase & Co. boosted their price target on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Cantor Fitzgerald upped their price target on AbbVie from $240.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, July 6th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Finally, Morgan Stanley lifted their price objective on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $269.29.

AbbVie Stock Performance

The company’s 50-day moving average price is $237.54 and its 200 day moving average price is $223.60. The stock has a market cap of $455.07 billion, a PE ratio of 126.88, a price-to-earnings-growth ratio of 0.87 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm’s revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the firm posted $2.46 earnings per share. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.14 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

Institutional Investors Weigh In On AbbVie

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC increased its stake in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. boosted its holdings in AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after buying an additional 789 shares during the period. Ieq Capital LLC boosted its holdings in AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after buying an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC increased its stake in AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after buying an additional 612,702 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.